A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate

Trial Profile

A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Nichiiko Pharmaceutical
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top